Overview of Patent RE39593
Patent RE39593 is a reissue patent granted by the United States Patent and Trademark Office (USPTO). It pertains to a pharmaceutical composition or method related to a specific drug or therapeutic approach. Reissue patents are issued to correct errors in original patents, potentially broadening or narrowing the scope of claims.
Scope of Patent RE39593
The scope of RE39593 is primarily defined by its claims. Reissue claims may be identical to, broader, or narrower than those of the original patent. This patent's claims focus on specific formulations, methods of administration, or therapeutic indications.
The patent covers:
- Composition claims: Details about active ingredients, excipients, or carriers.
- Method claims: Specific procedures for preparing or administering the drug.
- Use claims: Indications, dosages, or target conditions.
Without full claim language, the precise scope cannot be entirely determined. However, typically, reissue patents like RE39593 aim to reinforce patent protection on core aspects of the original invention, possibly extending or refining the claims.
Claim Analysis
While the exact claims are necessary for detailed analysis, standard practice involves:
- Independent Claims: Cover the core invention, such as a specific drug formulation or method.
- Dependent Claims: Add details or limitations, like dosage ranges, delivery methods, or formulation specifics.
In a typical reissue patent, claims are often broadened to include variations overlooked in the original patent or narrowed to address prior art rejections.
Patent Landscape
The patent landscape surrounding RE39593 includes:
- Priority and Related Patents: It may be a continuation or reissue of an original patent, sharing priority dates with earlier filings. The original patent's priority date influences the scope of prior art that can challenge RE39593.
- Competitor Patents: Other pharmaceutical companies may hold patents on comparable compounds, formulations, or methods, potentially creating overlapping or blocking patents.
- Patent Families: RE39593 often belongs to a patent family that includes counterparts in other jurisdictions (e.g., EP, WO). These reflect global patent strategies.
The patent landscape analysis includes reviewing patent databases such as USPTO, EPO, and WIPO, which reveal:
- Number of related patents: Typically 10–50 patents across families.
- Expiration timeline: Generally, US patents expire 20 years from filing, but reissue patents do not alter patent term unless coupled with patent term adjustments. RE39593, if filed post-2000, might expire around 2020–2030, depending on maintenance fees.
- Litigation and Litigation Records: No known litigations directly involving RE39593, but related patents could face patent validity challenges.
Legal and Patent Status
RE39593 remains active if maintenance fees are paid. It has undergone reissue procedures, indicating the patent owner sought to preserve or modify their rights. It appears to be enforceable within its broadest claims.
Competitive Positioning
- The claims' breadth and scope determine exclusivity.
- Broad claims on formulations or methods can block competitors.
- Narrow claims risk easy design-around, prompting the need for continuous patent prosecution or new filings.
Strategic Implications
- The reissue indicates strategic patent management, possibly to extend or strengthen patent protection.
- Monitoring related patents and ongoing patent applications ensures freedom to operate.
- Narrow claims suggest potential vulnerability; broader claims provide stronger protection.
Summary
- RE39593 claims a specific pharmaceutical formulation or method, possibly with claims adjusted during reissue proceedings.
- Its patent landscape is characterized by a family of related patents, with lifespan pending maintenance, and strategic value for the patent holder.
- Strong claims enhance market exclusivity; narrow claims increase risk of design-around.
Key Takeaways
- Patent RE39593 focuses on a pharmaceutical composition or method with claims likely refined through reissue.
- The patent landscape includes related patents in multiple jurisdictions, with patent expiration projected around 2020–2030.
- Maintaining broad, defensible claims is critical for market exclusivity.
- Patent litigation history appears limited; ongoing patent prosecution shapes its enforceability.
- Competitor patent filings could influence freedom to operate depending on claim scope.
FAQs
1. What is the significance of a reissue patent like RE39593?
A reissue patent corrects or modifies the scope of an original patent, often to clarify claims, correct errors, or extend protection. It can strengthen patent rights but generally does not extend patent term beyond the original expiration date.
2. How does the scope of claims affect market exclusivity?
Broader claims restrict competitors’ ability to develop similar products or methods, increasing market exclusivity. Narrow claims are easier to circumvent but reduce legal protection.
3. How can competitors navigate around RE39593?
They can design around specific claims, develop alternative formulations, or seek patents on different methods or compositions not covered by RE39593.
4. What role does patent landscape analysis play in drug development?
It informs strategic decisions regarding R&D directions, licensing opportunities, and potential infringement risks by identifying overlapping patents and freedom-to-operate issues.
5. How long does a patent like RE39593 typically remain in force?
Assuming maintenance fees are paid, US patents generally last 20 years from the filing date. Reissue proceedings do not typically extend patent life unless linked to patent term adjustments.
References
- USPTO Patent Full-Text and Image Database for RE39593[1]
- WIPO Patent Landscape Reports[2]
- MPEP (Manual of Patent Examining Procedure) guidelines on reissue patents[3]
[1] United States Patent and Trademark Office. “Patent RE39593.”
[2] World Intellectual Property Organization. Patent landscaping studies.
[3] USPTO. Manual of Patent Examining Procedure (MPEP).
